Trial reportMalaria journal2010
Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria.
Trial report in Malaria journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Outcomes reported in trials of treatments for severe malaria: The need for a core outcome set.Tropical medicine & international health : TM & IH · 2022Pooled it
- Pooled it
- Artemether for severe malaria.The Cochrane database of systematic reviews · 2019Pooled it
- Artemether for severe malaria.The Cochrane database of systematic reviews · 2014Pooled it
- Artesunate versus quinine for treating severe malaria.The Cochrane database of systematic reviews · 2012Pooled it
- In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam.Malaria journal · 2012Trial
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.Lancet (London, England) · 2010Trial
- Review
- From sixty-four percent hyperparasitemia to recovery: Managing severe falciparum malaria and delayed hemolytic anemia.IJID regions · 2025Article
- Health workers' adherence to malaria case management protocols in Northern Sudan: a qualitative study.Malaria journal · 2024Article
- Severe falciparum malaria in pregnancy in Southeast Asia: a multi-centre retrospective cohort study.BMC medicine · 2023Article
- Severe malaria.Malaria journal · 2022Review
- Advances and roadblocks in the treatment of malaria.British journal of clinical pharmacology · 2022Review
- Article
- Antimalarial and anticancer properties of artesunate and other artemisinins: current development.Monatshefte fur chemie · 2021Review
- Concomitant Bacteremia in Adults With Severe Falciparum Malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Article
- Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies.PLoS medicine · 2019Article
- Anaemia and malaria.Malaria journal · 2018Review
- Split dosing of artemisinins does not improve antimalarial therapeutic efficacy.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundBoth artemether and artesunate have been shown to be superior to quinine for the treatment of severe falciparum malaria in Southeast Asian adults, although the magnitude of the superiority has been greater for artesunate than artemether. These two artemisinin derivatives had not been compared in a randomized trial.
methodsA randomized double blind trial in 370 adults with severe falciparum malaria; 186 received intramuscular artesunate (2.4 mg/kg immediately followed by 1.2 mg/kg at 12 hours then 24 hours then daily) and 184 received intramuscular artemether (3.6 mg per kilogram immediately followed by 1.8 mg per kilogram daily) was conducted in Viet Nam. Both drugs were given for a minimum of 72 hours.
resultsThere were 13 deaths in the artesunate group (7 percent) and 24 in the artemether group (13 percent); P = 0.052; relative risk of death in the patients given artesunate, 0.54; (95 percent confidence interval 0.28-1.02). Parasitaemia declined more rapidly in the artesunate group. Both drugs were very well tolerated.
conclusionsIntramuscular artesunate may be superior to intramuscular artemether for the treatment of severe malaria in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.